Michael Gelband’s Esperion Therapeutics ESPR Stock Holding History

Michael Gelband’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.61M	Buy	+1,141,740	New	+$3.19M	0.02%	602
2026 Q1	–	Sell	-34,815	Closed	-$129K	–	1703
2025 Q4	$129K	Buy	+34,815	New	+$113K	﹤0.01%	1421
2024 Q4	–	Sell	-262,134	Closed	-$433K	–	1663
2024 Q3	$433K	Buy	262,134 +155,412	+146%	+$314K	﹤0.01%	1241
2024 Q2	$237K	Buy	106,722 +23,322	+28%	+$54.9K	﹤0.01%	1364
2024 Q1	$224K	Buy	+83,400	New	+$203K	﹤0.01%	1324
2023 Q2	–	Sell	-257,584	Closed	-$410K	–	1957
2023 Q1	$410K	Sell	257,584 -914,215	-78%	-$4.72M	﹤0.01%	1388
2022 Q4	$7.3M	Buy	1,171,799 +806,848	+221%	+$5.77M	0.11%	251
2022 Q3	$2.44M	Buy	364,951 +340,944	+1,420%	+$2.34M	0.03%	705
2022 Q2	$153K	Sell	24,007 -18,499	-44%	-$105K	﹤0.01%	1697
2022 Q1	$197K	Buy	42,506 +28,427	+202%	+$122K	﹤0.01%	1920
2021 Q4	$70K	Sell	14,079 -49,381	-78%	-$395K	﹤0.01%	2000
2021 Q3	$765K	Buy	+63,460	New	+$924K	0.01%	1158

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Michael Gelband's ESPR Position: Q2 2026 in Review

Michael Gelband opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 1,141,740 shares worth $3.61M. The stake represents 0.02% of the portfolio and ranks #602 among its holdings. This is a return to the name: Michael Gelband previously reported a position in ESPR as recently as Q4 2025.

Michael Gelband first reported a position in ESPR in Q3 2021 and has held it in 12 quarters since. The position peaked at $7.3M in Q4 2022. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Michael Gelband held 1,141,740 shares of Esperion Therapeutics worth $3.61M as of Q2 2026.
Esperion Therapeutics was a new Michael Gelband position in Q2 2026.
Esperion Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #602 holding.
Michael Gelband first reported a position in Esperion Therapeutics in Q3 2021 and has held it in 12 quarters since.
Michael Gelband's Esperion Therapeutics position peaked at $7.3M in Q4 2022.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.